NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

NCT04984811 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Non-Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Non Small Cell Lung Cancer

Interventions

DRUG: efineptakin alfa
DRUG: Atezolizumab

Sponsor

NeoImmuneTech

Collaborators

[object Object]